ACG clinical guideline: Primary sclerosing cholangitis

American Journal of Gastroenterology

Volumn 110, Issue 5, 2015, Pages 646-659

  Lindor, Keith D ^a,b   Kowdley, Kris V ^c   Harrison, M Edwyn ^b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c SWEDISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

URSODEOXYCHOLIC ACID; VANCOMYCIN; ANTIINFECTIVE AGENT; CHOLAGOGUE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CHOLANGIOGRAPHY; COLITIS; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC THERAPY; ENDOSCOPY; GALLBLADDER DISEASE; GENETIC ASSOCIATION; HUMAN; IMMUNOGLOBULIN G4 RELATED DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; METABOLIC BONE DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; SCLEROSING CHOLANGITIS; VITAMIN DEFICIENCY; CHOLANGITIS, SCLEROSING; COMPLICATION; DIGESTIVE SYSTEM NEOPLASMS; GALLSTONE; INFLAMMATORY BOWEL DISEASES;

ANTI-INFECTIVE AGENTS; CHOLAGOGUES AND CHOLERETICS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLANGITIS, SCLEROSING; DIGESTIVE SYSTEM NEOPLASMS; GALLSTONES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LIVER TRANSPLANTATION; URSODEOXYCHOLIC ACID;

EID: 84928928414     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.112     Document Type: Article

References (149)

1. Hirschfield GM, Karlsen TH, Lindor KD et al. Primary sclerosing cholangitis. Lancet 2013 ; 382 : 1587-99.
2. Dave M, Elmunzer BJ, Dwamena BA et al. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology 2010 ; 256 : 387-96.
3. Chapman R, Fevery J, Kalloo A et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010 ; 51 : 660-78.
4. Angulo P, Pearce DH, Johnson CD et al. Magnetic resonance cholangiography in patients with biliary disease: Its role in primary sclerosing cholangitis. J Hepatol 2000 ; 33 : 520-7.
5. Berstad AE, Aabakken L, Smith HJ et al. Diagnostic accuracy ofmagnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2006 ; 4 : 514-20.
6. Boonstra K, van Erpecum KJ, van Nieuwkerk KM et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis 2012 ; 18 : 2270-6.
7. O'Toole A, Alakkari A, Keegan D et al. Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012 ; 10 : 439-41.
8. Halliday JS, Djordjevic J, Lust M et al. A unique clinical phenotype of primary sclerosing cholangitis associated with crohn's disease. J Crohns Colitis 2012 ; 6 : 174-81.
9. Olsson R, Danielsson A, Jarnerot G et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991 ; 100 : 1319-23.
10. Karlsen TH, Franke A, Melum E et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010 ; 138 : 1102-11.
11. Ellinghaus D, Folseraas T, Holm K et al. Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifi es risk loci at GPR35 and TCF4. Hepatology 2013 ; 58 : 1074-83.
12. Melum E, Franke A, Schramm C et al. Genome-wide association analysis in primary sclerosing cholangitis identifi es two non-HLA susceptibility loci. Nat Genet 2011 ; 43 : 17-19.
13. Farrant JM, Doherty DG, Donaldson PT et al. Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology 1992 ; 16 : 390-5.
14. Mohamadnejad M, DeWitt JM, Sherman S et al. Role of EUS for preoperative evaluation of cholangiocarcinoma: A large single-center experience. Gastrointest Endosc 2011 ; 73 : 71-8.
15. Martin CR, Zaman MM, Ketwaroo GA et al. CFTR dysfunction predisposes to fibrotic liver disease in a murine model. Am J Physiol Gastrointest Liver Physiol 2012 ; 303 : G474-G481.
16. Grant AJ, Lalor PF, Salmi M et al. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002 ; 359 : 150-7.
17. Benhamou Y, Caumes E, Gerosa Y et al. AIDS-related cholangiopathy. critical analysis of a prospective series of 26 patients. Dig Dis Sci. 1993 ; 38 : 1113-8.
18. Grant AJ, Goddard S, Ahmed-Choudhury J et al. Hepatic expression of secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver disease. Am J Pathol 2002 ; 160 : 1445-55.
19. Pol S, Romana CA, Richard S et al. Microsporidia infection in patients with the human immunodeficiency virus and unexplained cholangitis. N Engl J Med 1993 ; 328 : 95-9.
20. Talwalkar JA, Angulo P, Johnson CD et al. Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 2004 ; 40 : 39-45.
21. Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol 2003 ; 98 : 1155-8.
22. Bjornsson E, Olsson R, Bergquist A et al. The natural history of smallduct primary sclerosing cholangitis. Gastroenterology 2008 ; 134 : 975-80.
23. Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: A long-term follow-up study. Hepatology 2002 ; 35 : 1494-500.
24. Bjornsson E, Boberg KM, Cullen S et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002 ; 51 : 731-5.
25. Lindor KD. Ursodiol for primary sclerosing cholangitis. mayo primary sclerosing cholangitis-ursodeoxycholic acid study group. N Engl J Med 1997 ; 336 : 691-5.
26. Mendes FD, Jorgensen R, Keach J et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006 ; 101 : 2070-5.
27. Bjornsson E, Chari ST, Smyrk TC et al. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology 2007 ; 45 : 1547-54.
28. Kamisawa T, Okamoto A. IgG4-related sclerosing disease. World J Gastroenterol 2008 ; 14 : 3948-55.
29. Boberg KM, Fausa O, Haaland T et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996 ; 23 : 1369-76.
30. Portmann B, Zen Y. Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation. Histopathology 2012 ; 60 : 236-48.
31. Chapman RW, Arborgh BA, Rhodes JM et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980 ; 21 : 870-7.
32. Bjornsson E, Chari S, Silveira M et al. Primary sclerosing cholangitis associated wiThelevated immunoglobulin G4: Clinical characteristics and response to therapy. Am J Ther 2011 ; 18 : 198-205.
33. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995 ; 332 : 924-33.
34. Wiesner RH, Grambsch PM, Dickson ER et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989 ; 10 : 430-6.
35. Angulo P, Peter JB, Gershwin ME et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000 ; 32 : 182-7.
36. Seibold F, Weber P, Klein R et al. Clinical significance of antibodies against neutrophils in patients withinflammatory bowel disease and primary sclerosing cholangitis. Gut 1992 ; 33 : 657-62.
37. Gossard AA, Angulo P, Lindor KD. Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol 2005 ; 100 : 1330-3.
38. Barnett KT, Malafa MP. Complications of hepatic artery infusion: a review of 4580 reported cases. Int J Gastrointest Cancer 2001 ; 30 : 147-60.
39. Castellano G, Moreno-Sanchez D, Gutierrez J et al. Caustic sclerosing cholangitis. report of four cases and a cumulative review of the literature. Hepatogastroenterology 1994 ; 41 : 458-70.
40. Alswat K, Al-Harthy N, Mazrani W et al. The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. Am J Gastroenterol 2012 ; 107 : 56-63.
41. Nakazawa T, Naitoh I, Hayashi K et al. Diagnosis of IgG4-related sclerosing cholangitis. World J Gastroenterol 2013 ; 19 : 7661-70.
42. Eaton JE, Silveira MG, Pardi DS et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011 ; 106 : 1638-45.
43. Mitchell SA, Bansi DS, Hunt N et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001 ; 121 : 900-7.
44. Harnois DM, Angulo P, Jorgensen RA et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001 ; 96 : 1558-62.
45. Olsson R, Boberg KM, de Muckadell OS et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study. Gastroenterology 2005 ; 129 : 1464-72.
46. Lindor KD, Kowdley KV, Luketic VA et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009 ; 50 : 808-14.
47. Stanich PP, Bjornsson E, Gossard AA et al. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis 2011 ; 43 : 309-13.
48. Al Mamari S, Djordjevic J, Halliday JS et al. Improvement of serum alkaline phosphatase to<1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2013 ; 58 : 329-34.
49. Lindstrom L, Hultcrantz R, Boberg KM et al. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2013 ; 11 : 841-6.
50. Schramm C, Schirmacher P, Helmreich-Becker I et al. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. a case series. Ann Intern Med 1999 ; 131 : 943-6.
51. Angulo P, Batts KP, Jorgensen RA et al. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000 ; 95 : 2333-7.
52. Martin CR, Blanco PG, Keach JC et al. The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis- A pilot study. Aliment Pharmacol Ther 2012 ; 35 : 255-65.
53. Bach N, Bodian C, Bodenheimer H et al. Methotrexate therapy for primary biliary cirrhosis. Am J Gastroenterol 2003 ; 98 : 187-93.
54. Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994 ; 106 : 494-9.
55. Farkkila M, Karvonen AL, Nurmi H et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebocontrolled trial. Hepatology 2004 ; 40 : 1379-86.
56. Silveira MG, Torok NJ, Gossard AA et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol 2009 ; 104 : 83-8.
57. Talwalkar JA, Angulo P, Keach JC et al. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients withan incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2005 ; 39 : 168-71.
58. Angulo P, Bharucha AE, Jorgensen RA et al. Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci 1999 ; 44 : 602-7.
59. Bharucha AE, Jorgensen R, Lichtman SN et al. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000 ; 95 : 2338-42.
60. Angulo P, MacCarty RL, Sylvestre PB et al. Pirfenidone in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2002 ; 47 : 157-61.
61. Boberg KM, Egeland T, Schrumpf E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol 2003 ; 38 : 991-5.
62. Talwalkar JA, Gossard AA, Keach JC et al. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int 2007 ; 27 : 451-3.
63. Davies YK, Cox KM, Abdullah BA et al. Long-term treatment of primary sclerosing cholangitis in children wiThoral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008 ; 47 : 61-7.
64. Stiehl A. Primary sclerosing cholangitis: the role of endoscopic therapy. Semin Liver Dis 2006 ; 26 : 62-8.
65. Johnson GK, Saeian K, Geenen JE. Primary sclerosing cholangitis treated by endoscopic biliary dilation: review and long-term follow-up evaluation. Curr Gastroenterol Rep 2006 ; 8 : 147-55.
66. Johnson GK, Geenen JE, Venu RP et al. Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment. Gastrointest Endosc 1991 ; 37 : 38-43.
67. Lee JG, Schutz SM, England RE et al. Endoscopic therapy of sclerosing cholangitis. Hepatology 1995 ; 21 : 661-7.
68. Kaya M, Petersen BT, Angulo P et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001 ; 96 : 1059-66.
69. Levy MJ, Baron TH, Clayton AC et al. Prospective evaluation of advanced molecular markers and imaging techniques in patients withindeterminate bile duct strictures. Am J Gastroenterol 2008 ; 103 : 1263-73.
70. Barr Fritcher EG, Kipp BR, Voss JS et al. Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. Am J Gastroenterol 2011 ; 106 : 2023-8.
71. Olsson R, Bjornsson E, Backman L et al. Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. J Hepatol 1998 ; 28 : 426-32.
72. van Milligen de Wit AW, Rauws EA, van Bracht J et al. Lack of complications following short-term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1997 ; 46 : 344-7.
73. Stiehl A, Rudolph G, Kloters-Plachky P et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002 ; 36 : 151-6.
74. Bjornsson E, Lindqvist-Ottosson J, Asztely M et al. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004 ; 99 : 502-8.
75. Gotthardt DN, Rudolph G, Kloters-Plachky P et al. Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after longterm treatment. Gastrointest Endosc 2010 ; 71 : 527-34.
76. Kaplan GG, Laupland KB, Butzner D et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a populationbased analysis. Am J Gastroenterol 2007 ; 102 : 1042-9.
77. Pohl J, Ring A, Stremmel W et al. The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2006 ; 18 : 69-74.
78. Bangarulingam SY, Gossard AA, Petersen BT et al. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol 2009 ; 104 : 855-60.
79. Rudolph G, Gotthardt D, Kloters-Plachky P et al. Infl uence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol 2009 ; 51 : 149-55.
80. Hammel P, Couvelard A, O'Toole D et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001 ; 344 : 418-23.
81. Baluyut AR, Sherman S, Lehman GA et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001 ; 53 : 308-12.
82. Kozarek RA. Endoscopic therapy in primary sclerosing cholangitis. dominant strictures may not matter: does that mean that endotherapy does not work? Am J Gastroenterol 2004 ; 99 : 509-10.
83. Lindberg B, Arnelo U, Bergquist A et al. Diagnosis of biliary strictures in conjunction wiThendoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis. Endoscopy 2002 ; 34 : 909-16.
84. Chapman MH, Webster GJ, Bannoo S et al. Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol 2012 ; 24 : 1051-8.
85. Burak K, Angulo P, Pasha TM et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004 ; 99 : 523-6.
86. Tischendorf JJ, Kruger M, Trautwein C et al. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy 2006 ; 38 : 665-9.
87. Meining A, Chen YK, Pleskow D et al. Direct visualization of indeterminate pancreaticobiliary strictures with probe-based confocal laser endomicroscopy: a multicenter experience. Gastrointest Endosc 2011 ; 74 : 961-8.
88. Farrell RJ, Agarwal B, Brandwein SL et al. Intraductal US is a useful adjunct to ERCP for distinguishing malignant from benign biliary strictures. Gastrointest Endosc 2002 ; 56 : 681-7.
89. Awadallah NS, Chen YK, Piraka C et al. Is there a role for cholangioscopy in patients with primary sclerosing cholangitis? Am J Gastroenterol 2006 ; 101 : 284-91.
90. Ginat D, Saad WE, Davies MG et al. Incidence of cholangitis and sepsis associated with percutaneous transhepatic biliary drain cholangiography and exchange: a comparison between liver transplant and native liver patients. AJR Am J Roentgenol 2011 ; 196 : W73-77.
91. Savader SJ, Trerotola SO, Merine DS et al. Hemobilia after percutaneous transhepatic biliary drainage: treatment with transcatheter embolotherapy. J Vasc Interv Radiol 1992 ; 3 : 345-52.
92. Choi SH, Gwon DI, Ko GY et al. Hepatic arterial injuries in 3110 patients following percutaneous transhepatic biliary drainage. Radiology 2011 ; 261 : 969-75.
93. Cameron JL, Pitt HA, Zinner MJ et al. Resection of hepatic duct bifurcation and transhepatic stenting for sclerosing cholangitis. Ann Surg 1988 ; 207 : 614-22.
94. Farges O, Malassagne B, Sebagh M et al. Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery 1995 ; 117 : 146-55.
95. Graziadei IW, Wiesner RH, Marotta PJ et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999 ; 30 : 1121-7.
96. Tung BY, Brentanall T, Kowdley KV et al. Diagnosis and prevalence of ulcerative colitis in patients with sclerosing cholangitis (abstract). Hepatology 1996 ; 24 : 169A.
97. Tischendorf JJ, Hecker H, Kruger M et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007 ; 102 : 107-14.
98. Fosby B, Karlsen TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 2012 ; 18 : 1-15.
99. Merion RM, Schaubel DE, Dykstra DM et al. The survival benefit of liver transplantation. Am J Transplant 2005 ; 5 : 307-13.
100. Kashyap R, Safadjou S, Chen R et al. Living donor and deceased donor liver transplantation for autoimmune and cholestatic liver diseases-an analysis of the UNOS database. J Gastrointest Surg 2010 ; 14 : 1362-9.
101. Goldberg D, Bittermann T, Makar G. Lack of standardization in exception points for patients with primary sclerosing cholangitis and bacterial cholangitis. Am J Transplant 2012 ; 12 : 1603-9.
102. Campsen J, Zimmerman MA, Trotter JF et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl 2008 ; 14 : 181-5.
103. Charatcharoenwitthaya P, Lindor KD. Recurrence of primary sclerosing cholangitis: what do we learn from several transplant centers? Liver Transpl 2008 ; 14 : 130-2.
104. Soetikno RM, Lin OS, Heidenreich PA et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002 ; 56 : 48-54.
105. Tsaitas C, Semertzidou A, Sinakos E. Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World J Hepatol 2014 ; 6 : 178-87.
106. Hansen JD, Kumar S, Lo WK et al. Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis. Dig Dis Sci 2013 ; 58 : 3079-87.
107. Charatcharoenwitthaya P, Enders FB, Halling KC et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008 ; 48 : 1106-17.
108. Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011 ; 54 : 1842-52.
109. Buckles DC, Lindor KD, Larusso NF et al. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 2002 ; 97 : 1138-42.
110. de Groen PC, Gores GJ, LaRusso NF et al. Biliary tract cancers. N Engl J Med 1999 ; 341 : 1368-78.
111. Kornfeld D, Ekbom A, Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study. Scand J Gastroenterol 1997 ; 32 : 1042-5.
112. Harnois DM, Gores GJ, Ludwig J et al. Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol 1997 ; 27 : 512-6.
113. Zenouzi R, Weismuller TJ, Hubener P et al. Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis. Clin Gastroenterol Hepatol 2014 ; 12 : 1733-8.
114. de Valle MB, Bjornsson E, Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a swedish population-based cohort. Liver Int 2012 ; 32 : 441-8.
115. Levy C, Lymp J, Angulo P et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005 ; 50 : 1734-40.
116. Boberg KM, Jebsen P, Clausen OP et al. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2006 ; 45 : 568-74.
117. Sinakos E, Saenger AK, Keach J et al. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol 2011 ; 9 : 434-9.
118. Bangarulingam SY, Bjornsson E, Enders F et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology 2010 ; 51 : 174-80.
119. Keiding S, Hansen SB, Rasmussen HH et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998 ; 28 : 700-6.
120. Fevery J, Buchel O, Nevens F et al. Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 2005 ; 43 : 358-60.
121. Eaton JE, Thackeray EW, Lindor KD. Likelihood ofmalignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol 2012 ; 107 : 431-9.
122. Gregorio GV, Portmann B, Karani J et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: A 16-year prospective study. Hepatology 2001 ; 33 : 544-53.
123. Bolier R, Oude Elferink RP, Beuers U. Advances in pathogenesis and treatment of pruritus. Clin Liver Dis 2013 ; 17 : 319-29.
124. Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. Clin Liver Dis 2012 ; 16 : 331-46.
125. Imam MH, Gossard AA, Sinakos E et al. Pathogenesis and management of pruritus in cholestatic liver disease. J Gastroenterol Hepatol 2012 ; 27 : 1150-8.
126. Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver diseases. Ann Intern Med 1975 ; 82 : 310-7.
127. Zein CO, Lindor KD, Angulo P. Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology 2004 ; 39 : 204-10.
128. Angulo P, Grandison GA, Fong DG et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011 ; 140 : 180-8.
129. Jorgensen RA, Lindor KD, Sartin JS et al. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol 1995 ; 20 : 215-9.
130. Wiest R, Groszmann RJ. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999 ; 19 : 411-26.
131. Sikuler E, Groszmann RJ. Interaction of flow and resistance in maintenance of portal hypertension in a rat model. Am J Physiol 1986 ; 250 : G205-212.
132. Abraham SC, Kamath PS, Eghtesad B et al. Liver transplantation in precirrhotic biliary tract disease: portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am J Surg Pathol 2006 ; 30 : 1454-61.
133. Garcia-Tsao G, Sanyal AJ, Grace ND et al. Practice Guidelines Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007 ; 46 : 922-38.
134. Kartheuser AH, Dozois RR, LaRusso NF et al. Comparison of surgical treatment of ulcerative colitis associated with primary sclerosing cholangitis: Ileal pouch-anal anastomosis versus brooke ileostomy. Mayo Clin Proc 1996 ; 71 : 748-56.
135. Lagier E, Rousseau H, Maquin P et al. Treatment of bleeding stomal varices using transjugular intrahepatic portosystemic shunt. J Pediatr Gastroenterol Nutr 1994 ; 18 : 501-3.
136. Adson MA, Fulton RE. The ileal stoma and protal hypertension: an uncommon site of variceal bleeding. Arch Surg 1977 ; 112 : 501-4.
137. Wiesner RH, LaRusso NF, Dozois RR et al. Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. Gastroenterology 1986 ; 90 : 316-22.
138. Naidu SG, Castle EP, Kriegshauser JS et al. Direct percutaneous embolization of bleeding stomal varices. Cardiovasc Intervent Radiol 2010 ; 33 : 201-4.
139. Teo TK, Sabri SS, Turba UC et al. Obliteration of bleeding peristomal varices with balloon-occluded retrograde transvenous obliteration using sodium tetradecyl sulfate foam. J Vasc Interv Radiol 2011 ; 22 : 1049-51.
140. Lindor KD, Gershwin ME, Poupon R et al. Primary biliary cirrhosis. Hepatology 2009 ; 50 : 291-308.
141. Gasser RW. Cholestasis and metabolic bone disease- A clinical review. Wien Med Wochenschr 2008 ; 158 : 553-7.
142. Angulo P, Therneau TM, Jorgensen A et al. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol 1998 ; 29 : 729-35.
143. Guichelaar MM, Schmoll J, Malinchoc M et al. Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors. Hepatology 2007 ; 4 : 1198-207.
144. Guanabens N, Pares A, Marinoso L et al. Factors infl uencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990 ; 85 : 1356-62.
145. Herlong HF, Recker RR, Maddrey WC. Bone disease in primary biliary cirrhosis: Histologic features and response to 25-hydroxyvitamin D. Gastroenterology 1982 ; 83 : 103-8.
146. Janes CH, Dickson ER, Okazaki R et al. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995 ; 95 : 2581-6.
147. Lindor KD, Janes CH, Crippin JS et al. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 1995 ; 21 : 389-92.
148. World HealThorganization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. report of a WHO study group. World HealThorgan Tech Rep Ser 1994 ; 843 : 1-129.
149. Zein CO, Jorgensen RA, Clarke B et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebocontrolled trial. Hepatology 2005 ; 42 : 762-71.